CGA
SRRA

Crescent Grove Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Crescent Grove Advisors’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,786
Closed -$570K – 305
2022
Q1 		$570K Hold
17,786
– – 0.06% 162
2021
Q4 		$387K Buy
+17,786
New +$392K 0.04% 201

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Crescent Grove Advisors's SRRA Position: Q2 2022 in Review

Crescent Grove Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 17,786 shares — an estimated $570K sold.

Crescent Grove Advisors first reported a position in SRRA in Q4 2021 and held it in 2 quarters. The position peaked at $570K in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

  • Crescent Grove Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Crescent Grove Advisors sold 17,786 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $570K.
  • Crescent Grove Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Crescent Grove Advisors's Sierra Oncology, Inc. Common Stock position peaked at $570K in Q1 2022.
  • 109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on Crescent Grove Advisors's 13F filing for Q2 2022, filed 20 Jul 2022.